Mandeep Kaur Mann

Mandeep Kaur Mann

Auto-generated profile, based on publicly available information

Mandeep Kaur Mann

Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
EDEllen Van Damme
Ellen Van Damme
PAPravien Abeywickrema
Pravien Abeywickrema
YYYanting Yin
Yanting Yin
JXJiexiong Xie
Jiexiong Xie
SJSofie Jacobs
Sofie Jacobs
MLMarnix Van Loock
Marnix Van Loock
The membrane (M) protein of betacoronaviruses is well conserved and has a key role in viral assembly1,2. Here we describe the identification of JNJ-9676, a small-molecule inhibitor targeting the coronavirus M protein. JNJ-9676 demonstrates in vitro nanomolar antiviral activity against SARS-CoV-2, SARS-CoV and sarbecovirus strains from bat and pangolin zoonotic origin. Using cryogenic electron microscopy (cryo-EM), we determined a binding pocket of JNJ-9676 formed by the transmembrane domains of the M protein dimer. Compound binding stabilized the M protein dimer in an altered conformational state between its long and short forms, preventing the release of infectious virus. In a pre-exposure Syrian golden hamster model, JNJ-9676 (25 mg per kg twice per day) showed excellent efficacy, illustrated by a significant reduction in viral load and infectious virus in the lung by 3.5 and 4 log10-transformed RNA copies and 50% tissue culture infective dose (TCID50) per mg lung, respectively. Histopathology scores at this dose were reduced to the baseline. In a post-exposure hamster model, JNJ-9676 was efficacious at 75 mg per kg twice per day even when added at 48 h after infection, when peak viral loads were observed. The M protein is an attractive antiviral target to block coronavirus replication, and JNJ-9676 represents an interesting chemical series towards identifying clinical candidates addressing the current and future coronavirus pandemics.

14 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMMandeep K. Mann
Mandeep K. Mann
CZCarlos A. Zepeda-Velázquez
Carlos A. Zepeda-Velázquez
HGHéctor González-Álvarez
Héctor González-Álvarez
ADAiping Dong
Aiping Dong
TKTaira Kiyota
Taira Kiyota
MSMatthieu Schapira
Matthieu Schapira

30 October 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMMandeep Kaur Mann
Mandeep Kaur Mann
IFIvan Franzoni
Ivan Franzoni
RFRenato Ferreira de Freitas
Renato Ferreira de Freitas
WTWolfram Tempel
Wolfram Tempel
SHScott Houliston
Scott Houliston
MSMatthieu Schapira
Matthieu Schapira

27 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RHRachel Harding
Rachel Harding
IFIvan Franzoni
Ivan Franzoni
MMMandeep K. Mann
Mandeep K. Mann
MSMagdalena M. Szewczyk
Magdalena M. Szewczyk
BMBijan Mirabi
Bijan Mirabi
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Histone deacetylase 6 (HDAC6) inhibition is an attractive strategy for treating numerous cancers, and HDAC6 catalytic inhibitors are currently in clinical trials. The HDAC6 zinc-finger ubiquitin-binding domain (UBD) binds free C-terminal diglycine motifs of unanchored ubiquitin polymer chains and protein aggregates, playing an important role in autophagy and aggresome assembly. However, targeting this domain with small molecule antagonists remains an underdeveloped avenue of HDAC6-focused drug discovery. We report SGC-UBD253 (25), a chemical probe potently targeting HDAC6-UBD in vitro with selectivity over nine other UBDs, except for weak USP16 binding. In cells, 25 is an effective antagonist of HDAC6-UBD at 1 μM, with marked proteome-wide selectivity. We identified SGC-UBD253N (32), a methylated derivative of 25 that is 300-fold less active, serving as a negative control. Together, 25 and 32 could enable further exploration of the biological function of the HDAC6-UBD and investigation of the therapeutic potential of targeting this domain.

9 September 2022 in ACS Chemical Biology
Verified
Journal Article
Closed access
SBSamir H. Barghout
Samir H. Barghout
MMMandeep K. Mann
Mandeep K. Mann
AAAhmed Aman
Ahmed Aman
YYYifan Yu
Yifan Yu
MAMatthew G. Alteen
Matthew G. Alteen
DBDalia Barsyte-Lovejoy
Dalia Barsyte-Lovejoy

24 November 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
MMMandeep Kaur Mann
Mandeep Kaur Mann
YYYanting Yin
Yanting Yin
SMSimone Marsili
Simone Marsili
JXJiexiong Xie
Jiexiong Xie
JDJordi Doijen
Jordi Doijen
PAPravien Abeywickrema
Pravien Abeywickrema
The membrane (M) protein of coronaviruses is essential for maintaining structural integrity during membrane virion budding and viral pathogenesis. Given its high conservation in lineages within the betacoronavirus genus, such as sarbecoviruses, the M protein presents as an attractive therapeutic target; however, developing broad-spectrum antivirals targeting coronaviruses such as MERS-CoV is challenging due to lower sequence conservation and limited structural information available beyond that of the SARS-CoV-2 M protein. In this study, we report 3-3.2 Å resolution structures of MERS-CoV M protein, engineered with a SARS-CoV-2-like antibody interface, representing the first human merbecovirus M protein structure, and SARS-CoV M protein structures, with and without a previously identified SARS-CoV-2 M protein inhibitor, JNJ-9676. We highlight the structural differences between the MERS-CoV, SARS-CoV and SARS-CoV-2 M proteins, and present insights into the conservation of the JNJ-9676 binding pocket as well as key differences that could be targeted to accelerate the design of specific MERS-CoV and broad-spectrum antivirals targeting coronavirus M proteins.